Nature

Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup

Hypertrophic cardiomyopathy (HCM) is considered a hereditary autosomal dominant condition, but genetic testing is positive in only half of patients. In patients with negative genetic tests, the ...
Nasdaq

Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care

Cytokinetics has launched EARTH-HCM, an interactive online tool aimed at improving awareness and understanding of hypertrophic cardiomyopathy (HCM) in the U.S. Developed with input from prominent ...
Healthline

Testing for Hypertrophic Cardiomyopathy: Who Should Get It and How It Works

Testing for hypertrophic cardiomyopathy is primarily recommended for individuals with a first-degree relative diagnosed with the condition, as well as for people experiencing symptoms like chest pain, ...
Nasdaq

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and ...